Avalo Therapeutics, Inc. (AVTX)
AVTXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$7.27
+0.3400 (+4.91%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $420.37m
- P/E
- –
- EPS, last 4 quarters
- $-2.52
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.53 to $24.27
- Average volume
- 1.80m
- Previous close
- $6.93
Analysts
8 coveringBuy5 buy, 3 hold, 0 sell
Targets a year out average $26.00, +257.6% from here
Earnings
next estimate $-0.5900Next report
Dec 2025
+76.0%
Mar 2026
+2.0%
Jun 2026
-25.8%
Sep 2026
+46.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | $59.0k | – | – |
| Gross profit | – | $59.0k | – | – |
| Operating income | -$19.20m | -$19.74m | -$20.90m | -$31.52m |
| Net income | -$30.63m | -$13.72m | -$19.63m | -$36.36m |
News
8 latest- Avalo Therapeutics, Inc. Enters $200,000,000 At-The-Market Offering Program and Terminates Prior AgreementFintel · 4 days ago
- Avalo Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and $462.8 million in CashFintel · 4 days ago
- Noteworthy Friday Option Activity: OFG, AVTX, VSTBNK Invest · Sep 25, 2026
- Avalo Appoints Ron Philips To Its Board Of Directors; Abdakibart Phase 3 Set For H1 2027 RTTNews · Jun 24, 2026
- Avalo Therapeutics (AVTX) Price Target Increased by 18.49% to 47.94Fintel · May 14, 2026
- Avalo Prices $375M Offering Following Strong Phase 2 Abdakibart Data; Stock Up RTTNews · May 6, 2026
- Wolfe Research Initiates Coverage of Avalo Therapeutics (AVTX) with Outperform RecommendationFintel · Apr 9, 2026
- Citizens Initiates Coverage of Avalo Therapeutics (AVTX) with Market Outperform RecommendationFintel · Apr 6, 2026
The company
Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1 pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1 monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1 driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1 mAb.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- avalotx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.